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Giant amphiphiles encompassing a hydrophilic β-cyclodextrin (βCD) component and a
hydrophobic calix[4]arene (CA4) module undergo self-assembly in aqueous media to
afford core-shell nanospheres or nanocapsules, depending on the nanoprecipitation
protocol, with high docetaxel (DTX) loading capacity. The blank and loaded
nanoparticles have been fully characterized by dynamic light scattering (DLS), ζ-potential
measurements and cryo-transmission electron microscopy (cryo-TEM). The data are
compatible with the distribution of the drug between the nanoparticle core and the
shell, where it is probably anchored by inclusion of the DTX aromatic moieties in
βCD cavities. Indeed, the release kinetics profiles evidenced an initial fast release of
the drug, which likely accounts for the fraction hosted on the surface, followed by
a slow and sustained release rate, corresponding to diffusion of DTX in the core,
which can be finely tuned by modification of the giant amphiphile chemical structure.
The ability of the docetaxel-loaded nanoparticles to induce cellular death in different
prostate (human LnCap and PC3) and glioblastoma (human U87 and rat C6) cells was
also explored. Giant amphiphile-based DTX formulations surpassing or matching the
antitumoral activity of the free DTX formulation were identified in all cases with no need
to employ any organic co-solvent, thus overcoming the DTX water solubility problems.
Moreover, the presence of the βCD shell at the surface of the assemblies is intended to
impart stealth properties against serum proteins while permitting nanoparticle surface
decoration by supramolecular approaches, paving the way for a new generation of
molecularly well-defined antitumoral drug delivery systems with improved specificity and
efficiency. Altogether, the results provide a proof of concept of the suitability of the
approach based on βCD-CA4 giant amphiphiles to access DTX carriers with tunable
properties.
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INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed cancer
in men and it is one of the leading causes of death worldwide
(Zhou et al., 2016). In the early-stage, PCa is androgen-dependent
for growth and survival, and androgen ablation therapy usually
causes its regression. However, some of the PCas evolve to
aggressive and drug-resistant tumors. Docetaxel (DTX) is a
second-generation cytotoxic agent derived from taxol which has
been proven to have significant antitumor activity against various
human cancers, including PCa (Sweeney et al., 2015; James et al.,
2016), metastasized glioblastoma (Astner et al., 2006), HER-2
positive metastatic breast cancer (Swain et al., 2015) and lung
cancer (Shaw et al., 2013). Docetaxel binds preferentially to the
tubulin β-subunit, stabilizing the microtubules and inhibiting
depolymerization, which leads to cell cycle arrest, mainly in
the G2/M phase, and, ultimately, to cell death by apoptosis
(Montero et al., 2005). Regrettably, resistance to docetaxel
appears frequently during therapy, possibly involving several
mechanisms such as over expression of drug eﬄux pumps,
acquired mutations of the drug binding site in tubulin or
activation of growth factor survival pathways (Dumontet and
Sikic, 1999; Gottesman et al., 2002), which becomes a major
limitation for the therapeutic use of the drug (Giannakakou et al.,
2000; He et al., 2001).
Due to its poor aqueous solubility (10–20 mM in plain water),
DTX is currently formulated in polysorbate 80 (Taxotere R©)
in anhydrous form, since DTX degrades over time in protic
solvents (Rao et al., 2006). This formulation is known to
cause severe allergic reactions and peripheral neuropathy (ten
Tije et al., 2003) the incidence of hypersensitivity ranging
from 5 to 40%. Moreover, after dilution with the 13%
hydroethanolic vehicle provided, the adverse effects may be
intensified and the formulation becomes physically unstable and
must be administered to the patient within 8 h. Investigational
approaches have focused in macromolecular multiconjugates
or nanoparticles as solubilizing and delivery agents since
such constructs generally protect DTX from degradations,
benefit from passive targeting to tumoral tissues by enhanced
permeability and retention (EPR) effect, and can be modified
with specific groups for tumor-specific targeting (Zhang and
Zhang, 2013). Examples of nanometric platforms used in the
design of DTX formulations on record include low molecular
weight chitosan (Lee et al., 2009), dendrimers (Gajbhiye and
Jain, 2011), lipid-based formulations (Ren et al., 2016), C60
fullerene (Raza et al., 2015) and gold nanoparticles (Francois
et al., 2011). Whereas significant improvements in drug
biodistribution and tumoricidal efficiency have been reported, the
intrinsic polydispersity of such systems represents a limitation
for structure-activity relationship (SAR) and optimization
studies that may seriously hamper translation into hospital
settings.
An ideal DTX formulation should rely on molecularly well-
defined vehicles, susceptible of physicochemical tailoring in order
to impart biocompatibility, efficiency to the target cells, and
high drug loading with appropriate drug release characteristics,
thereby preventing drug inefficiency and side effects. Precision
macromolecular synthesis represents a unique approach for
those purposes, since it allows engineering structures across
multiple length scales with accurate control of their self-
assembling and macroscopic properties, and offers considerable
potential for the encapsulation, delivery and controlled release of
pharmaceuticals. This goal can be realized by linking shape- and
volume-persistent nano-objects with a well-defined molecular
structure and specific symmetry, generically termed molecular
nanoparticles (MNPs). The control of hierarchical structures
from the resulting “giant molecules” can then be facilitated by
tuning the collective physical interactions between the relatively
independent nanosized subunits. Among giant molecules,
giant surfactants have shown self-assembling properties that
are extremely sensitive to topological variations, providing
unprecedented opportunities for the design and programming of
advanced materials possessing a specific functionality (Yu et al.,
2013).
In a preliminary publication, we previewed an original
giant surfactant prototype based on β-cyclodextrin (βCD) and
calix[4]arene (CA4) heterodimers with the capability to self-
assemble into core-shell nanosystems with drug encapsulation
and controlled release capabilities (Gallego-Yerga et al., 2014).
βCD, the most accessible representative of the cyclodextrin
(CD) family, is a water-soluble macrocyclic compound made of
seven α(1,4)-linked glucose units that feature a truncated-cone
shape with an external hydrophilic surface and a hydrophobic
cavity that can host different molecules and transport them in
biological media (Kurkov and Loftsson, 2013; James et al., 2016).
Interestingly, CDs can be chemically modified and decorated
with targeting groups, which has been exploited for site-specific
drug delivery to different cell types, such as macrophages (Benito
et al., 2004). Of particular interest for our goals is the fact that
βCD can form inclusion complexes with docetaxel and that the
incorporation of βCD in nanomaterials can be used to impart
high DTX loading capabilities (Zhao and Astruc, 2012; Wang
et al., 2016). Although canonic βCD exhibit some renal toxicity
after parenteral administration, related to its greater ability to
interact with cellular lipids leading to cell-membrane damage,
toxicity is greatly reduced after chemical modification (Stella
and He, 2008; Gallego-Yerga et al., 2015a). Indeed, amphiphilic
βCD derivatives showed no apparent toxicity in animal models
(Mendez-Ardoy et al., 2011; Aranda et al., 2013; Gallego-Yerga
et al., 2015a).
Similarly, calixarenes (CAs) are macrocyclic molecules formed
by para-substituted phenol units linked through methylene
bridges that likewise form a cavity that can host cations, amino
acids or peptides (Sansone et al., 2010). Although DTX does
not match the cavity size of calixarene hosts, nanocarriers
constructed from amphiphilic calix[4]arene derivatives have
shown excellent taxane drug loading capabilities (Weeden et al.,
2012). The combination of βCD and CA4 elements in a single
macromolecule has therefore the potential of benefiting from
the favorable properties of both entities for DTX transport and
delivery (Wang et al., 2013).
Herein we report the preparation of self-assembled
nanocapsules (NCs) and nanospheres (NSs) from the giant
surfactants 1 and 2, obtained by “click”-type heterodimerization
Frontiers in Pharmacology | www.frontiersin.org 2 May 2017 | Volume 8 | Article 249
fphar-08-00249 May 4, 2017 Time: 16:29 # 3
Gallego-Yerga et al. Anticancer Effect of Docetaxel Delivered by Nanoparticles
of regioselectively functionalized hydrophilic βCD and
hydrophobic CA4 MNPs (Figure 1). The resulting multicavity
systems have been characterized in terms of their hydrodynamic
diameter, ζ-potential and morphology by dynamic light
scattering, electrophoretic mobility and cryo-transmission
electron microscopy techniques. After DTX-loading, the
resulting formulations have shown efficient cytotoxic activity
in two human cell lines of PCa (LnCap and PC3) and in
two glioblastoma cell lines of human (U87) and murine (C6)
origin. Altogether the results demonstrate the suitability of the
approach based on βCD-CA4 hybrid molecules to generate DTX
nanocarriers with varied properties. Moreover, the fact that the
best performing formulation in terms of cytotoxicity depends
on the target cell line highlights the importance of developing
strategies that not only keep full control on the chemical structure
of the MNP, but that are also molecular diversity-oriented and
compatible with SAR analysis. Previous reports supporting that
nanoencapsulation of DTX bears considerable promise for the
FIGURE 1 | Synthesis of the CA4−βCD giant surfactants and schematic representation of their self-assembly into nanospheres and nanocapsules.
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development of oral formulations represent a further motivation
for this research (Attili-Qadri et al., 2013; Cho et al., 2014).
Nevertheless, ADME-Tox and pharmacokinetic studies are out
of the scope of the present work.
MATERIALS AND METHODS
Synthesis and Characterization
The CA4-βCD giant surfactants 1 and 2 were obtained by
high-yielding “click”-type thiourea coupling reactions between
the isothiocyanate-armed tetraalkylated CA4 derivative 4 or
5 and the amine-equipped βCD derivative 3 (Figure 1),
using a previously optimized semi-convergent synthetic strategy
(Gallego-Yerga et al., 2014). The βCD precursor 3 was
prepared in 92% yield from the known mono-O6-tosyl-
derivative 3 (Kaneda et al., 2002) after reaction with Boc-
protected cysteamine and final acid-catalyzed hydrolysis (→4).
The synthesis of the CA4 counterparts started from the singly
functionalized derivatives 5 and 6, accessed by mononitration
of the corresponding lower-ring tetra-hexyl and -dodecyl ethers,
which proceeded in 75% after treatment with concentrated
nitric acid in a mixture of dichloromethane and glacial acetic
acid (Keldermann et al., 1992). Sequential reduction to the
corresponding amines followed by isothiocyanation afforded
the intermediates 7 and 8. Thiourea coupling with mono-Boc-
protected butylethylenediamine, carbamate hydrolysis and final
isothiocyanation proceeded with over 90% yield in every step.
Thiourea conjugation of βCD 4 with the CA4 partners 7 and 8
provided the target heterodimers 1 and 2 in 83 and 90% yield,
respectively.
Hydrodynamic Diameter and ζ-Potential
Measurements
The average sizes of the self-assembled nanoparticles (NSs
or NCs) were measured using a Zetasizer Nano ZS (Malvern
Instruments) with the following specifications: sampling time,
automatic; number of measurements, 3 per sample; medium
viscosity, 1.054 cP; refractive index, 1.33; scattering angle,
173◦; λ = 633 nm; temperature, 25◦C. Data were analyzed
using the multimodal number distribution software included
in the instrument. ζ-Potentials were determined using the
“mixed-mode measurement” phase analysis light scattering
(M3-PALS) following the specifications used for hydrodynamic
diameter measurements. Before each series of experiments, the
performance of the instruments was checked with either 90-nm
monodisperse latex beads (Coulter) for DLS or with DTS 50
standard solution (Malvern) for ζ-potentials.
Cryo-Transmission Electron Microscopy (Cryo-TEM)
The transmission electron microscope used to obtain cryo-TEM
micrographs of blank and DTX-loaded NSs and NCs was a
JEOL JEM 1400 instrument operating at 120 kV. To prepare the
samples, 5 µL of the NS or NC suspension was deposed on a
QUANTIFOIL R© R 1.2/1.3 grid and the excess was eliminated with
Whatman N◦1 paper. Vitrification was done with a CPC Leica
by immersing the grid as fast as possible in liquid ethane. The
measurements were carried out at the facilities of the Center for
Biological Research (CSIC, Madrid, Spain).
Preparation of Unloaded (Blank) Nanospheres
Blank NS suspensions were prepared using the nanoprecipitation
technique (Skiba et al., 1996) by taking advantage of the
spontaneous self-assembling capabilities of the amphiphilic βCD-
calixarene heterodimer derivatives 1 and 2 when dispersed into
an aqueous phase. Briefly, the corresponding giant surfactant
species was dissolved in anhydrous methanol to a final
concentration of 0.4 mM, and this solution was dropwise
added into an equal volume of milliQ water containing a non-
ionic hydrophilic surfactant (Polysorbate 80, 2 mg·mL−1), under
magnetic stirring (300 rpm) at 25◦C for 5 min. Nanoparticles
were formed spontaneously and the organic solvent was removed
under reduced pressure at 35◦C. The nanoparticle suspensions,
prepared in triplicate, were subjected to centrifugation (1,957× g,
15 min) to remove traces of any aggregated giant amphiphile and
stored in closed vials at+4◦C.
Preparation of Docetaxel-Loaded Nanospheres
Docetaxel-loaded NS formulations were prepared using the
procedure described above, but starting from methanol solutions
containing both the corresponding amphiphilic derivative 1 or
2 (0.4 mM) and DTX (1.2 mM). The aqueous NS suspensions,
prepared in triplicate, were subjected to centrifugation (1,957× g
rpm, 15 min) to remove traces of unloaded (insoluble) docetaxel
that might potentially precipitate or any aggregated giant
amphiphile and stored in closed vials at 4◦C.
Preparation of Unloaded (Blank) Nanocapsules
The corresponding giant surfactant 1 or 2 was dissolved in
anhydrous methanol at 0.4 mM containing a small amount
of capric/caprylic triglycerides (Labrafac Lipophile WL1349,
2 mg·mL−1) and a non-ionic hydrophobic surfactant (Span 80,
2 mg·mL−1). This solution was added dropwise into an equal
volume of milli-Q water containing a non-ionic hydrophilic
surfactant (Polysorbate 80, 2 mg·mL−1), under magnetic stirring
(300 rpm) at 25◦C for 5 min. Blank NCs were thus formed
spontaneously. The organic solvent was removed under reduced
pressure at 35◦C and the resulting aqueous suspensions, prepared
in triplicate, were subjected to centrifugation (1,957× g, 15 min)
to remove traces of any aggregated giant amphiphile and stored
in closed vials at+4◦C.
Preparation of Docetaxel-Loaded Nanocapsules
Docetaxel-loaded NC suspensions were prepared using the
procedure described above, but starting with methanol solutions
containing both the corresponding amphiphilic derivative 1 or 2
(0.4 mM) and docetaxel (1.2 mM). The NC suspensions, prepared
in triplicate, were subjected to centrifugation (1,957× g, 15 min)
to remove traces of unloaded (insoluble) docetaxel or aggregated
giant amphiphile and stored in closed vials at+4◦C.
Determination of DTX Encapsulation Efficiency and
Loading Capacity
The supernatant obtained after centrifugation (1,957× g, 15 min)
of the corresponding DXT-loaded NSs or NCs suspensions was
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freeze-dried, solubilized in methanol and the DTX concentration
determined spectrophotometrically (Jasco UV-630 spectrometer)
at 230 nm and 25◦C by absorbance interpolation in a calibration
plot. We run control experiments to ensure that the giant
amphiphiles 1 or 2 did not interfere in determination of
encapsulated DTX. Indeed, the βCD unit does not absorb in
the UV and the calix moiety have two absorption maxima
at 280 and 288 nm, far enough from the 230 nm maximum
of DTX. The encapsulation efficiency (EE; %) was determined
as the quotient (w/w; x100) between the entrapped drug (i.e.,
total minus unbound drug) and the total drug used in the
formulation. The loading capacity LC (%) is obtained as the
quotient (w/w; x100) between the entrapped drug and the total
amount of encapsulated drug and giant amphiphile used in the
formulation.
In Vitro Docetaxel Release Kinetics
In vitro DTX release kinetics studies were performed by dialysis
(cutoff of 12 kDa, Sigma) in a phosphate buffer saline medium
(PBS, 0.01 M, pH 7.3, 37 ◦C). DTX-loaded NS or NC suspensions,
prepared as described above, were dialyzed against 125 mL of
PBS under smooth stirring. Aliquots were withdrawn every hour,
measured spectrophotometrically at 230 nm and then returned
to the system. Released DTX was determined by absorbance
interpolation in a PBS calibration curve.
Cell Culture
LnCaP and PC3 human PCa and C6 and U87 glioblastoma cell
lines were obtained from ATCC (Manassas, VA, USA). The cells
were grown in DMEM supplemented with 2 mM l-glutamine,
20 units/mL penicillin, 5 µg/mL streptomycin and 10% heat-
inactivated fetal calf serum (Gibco, Whaltman, MA, USA). Cells
were maintained at 37◦C in a saturated humidity atmosphere
containing 95% air and 5% CO2.
Lactate Dehydrogenase Assay
Lactate dehydrogenase (LDH) toxicity assays were performed
by measuring the release of LDH to the culture medium
using the CytoTox96 R© Non-Radioactive Cytotoxicity Assay kit
(Promega, Madison, WI, USA) as previously described (Posadas
et al., 2009). Briefly, tumoral cells were incubated for 72 h
with free DTX (ranging from 0.1 to 1 µM) or different
heterodimer formulations (nanocapsules or nanospheres), at
increasing concentrations, loaded or not with DTX. The final
nanoparticle concentration was adjusted to obtain the loaded
DTX concentration that matched the free DTX concentration
used in control experiments (0.1 to 1 µM). After treatment,
the supernatants were collected and the intact cells were lysed
using 0.1% (w/v) Triton X-100 in (0.9%) NaCl. Both the LDH
released to culture media, as well as the LDH content within
the cells, were determined spectrophotometrically at 490 nm on
a 96-well plate reader (Infinite 200, Tecan, Salzburg, Austria)
following the manufacturer’s instructions. LDH release was
defined by the ratio LDH released/total LDH present in the cells,
with the total LDH being 100%. All the samples were run in
quadruplicate.
Statistical Analysis
The non-parametric variance analysis (Kruskal–Wallis), followed
by Dunn’s test, were used to evaluate statistical differences
between groups. P < 0.05 was considered statistically significant.
Statistical analyses were conducted using SPSS 13.0 (SPSS,
Chicago, IL, USA).
RESULTS
Preparation and Characterization of
Self-Assembled Nanospheres and
Nanocapsules from Giant Surfactants 1
and 2
The interfacial solvent displacement method (Méndez-Ardoy
et al., 2012) was used to engineer self-assembled nanospheres and
nanocapsules from the CA4-βCD macromolecular constructs 1
and 2. Dispersion of methanol solutions of the heterodimers into
water containing a non-ionic hydrophilic surfactant (Polysorbate
80) instantaneously formed blank (unloaded) nanospheres.
Evaporation of the organic solvent under reduced pressure
allowed obtaining the nanoparticle suspension in water. For
nanocapsule elaboration, pharmaceutically approved synthetic
triglycerides (Labrafac Lipophile WL1349) were added to the
organic phase containing the giant surfactant. Then, the
solution was dropped into the aqueous phase to produce blank
nanocapsules. Docetaxel-loaded NSs and NCs were prepared in
a similar manner by co-formulation of the heterodimers and
the drug (1:3 molar ratio) in the methanol solution followed by
nanoprecipitation. The encapsulation efficiencies thus obtained
ranked from 89% (for 1-NS) and 83% (for 2-NS) to 99% (for
1-NC) and 98% (for 2-NC), which are among the highest
reported for docetaxel nanoformulations (Youm et al., 2011;
Lollo et al., 2014). Most interestingly, the loading capacities
(entrapped DXT/total amount of giant amphiphile and entrapped
DTX, w/w, x100) were outstandingly high: 73% for 1-NS, 71% for
2-NS, 75% for 1-NC and 74% for 2-NC. The higher encapsulation
efficiencies and loading capacities of nanocapsules, for a given
giant surfactant entity, is consistent with the higher affinity of
the strongly hydrophobic drug for the lipidic phase (triglycerides)
at the inner core of these formulations. In any case, these
values compare very favorably with data reported for other DXT-
encapsulating systems, which typically exhibit loading capacities
between 5 and 15% (Elsabahy et al., 2007; Hwang et al., 2008;
Qi et al., 2013; Conte et al., 2016). It is worth noting that the
mass ratio of DTX in the new nanospheres and the nanocapsules
with respect to the total amount of excipients in the formulations
(MNP 1 or 2 plus surfactant in the case of the NSs; MNP 1
or 2 plus oil plus surfactants in the case of NCs) is very close
to 1 (1:1.1 for 1-NS, 1:1.2 for 2-NS, 1.0:1.02 for 1-NC and
1.16 for 2-NC), over one-order-of-magnitude lower than the
1:26 DTX:Polysorbate 80 mass ratio in the DTX commercial
formulation Taxotere R©.
The colloidal dispersions of blank or DTX-loaded NSs and
NCs remained stable for more than 30 days both at room
temperature and at 37◦C. Dynamic light scattering (DLS)
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showed unimodal distributions of nanoparticle sizes, which
remained unaltered for the whole 30-day’s period, with a
small polydispersity index and negative ζ-potential in all cases
(Table 1). Results are given as volume distribution of the major
population by the mean diameter with its standard deviation.
No significant differences were encountered when the data were
expressed in intensity, volume or number distributions. This
is consistent with a spherical topology of the nanoparticles.
For blank nanospheres and nanocapsules, the hydrodynamic
diameters ranged from 120 to 189 nm. When loaded with
docetaxel, nanospheres decreased their hydrodynamic size to
20–35 nm (Table 1). In contrast, DTX-loaded nanocapsules
exhibited hydrodynamic diameters in the range 200–265 nm,
slightly higher as compared with the blank nanocapsules. Both
NSs and NCs experienced a significant increase in ζ-potential
upon loading with DTX, from about −35 to −15 mV, strongly
suggesting that the drug locates in part at the nanoparticle
surface, probably in the βCD cavities.
Cryo-transmission electron microscopy (cryo-TEM)
micrographs of the blank and DTX-loaded NSs and NCs
evidenced quasi-spherical morphologies in all cases (Figure 2).
Interestingly, the images reproduce the effect of DTX-loading on
the size of the self-assembled nanoparticles already observed by
DLS, that is, a moderate increase in the case of the nanocapsules
(from about 80 to about 150 nm diameter; Figure 2D vs.
Figure 2B), and a very significant decrease in the case of the
NSs (from about 80 to about 15 nm; Figure 2C vs. Figure 2A).
Most probably, blank nanospheres are formed by the aggregation
of smaller entities, in agreement with previous atom force
microscopy (AFM) observations. This hierarchical aggregation
process is probably driven by hydrogen bonding interactions
involving the βCD moieties at the surface of the NSs. It is
interesting to speculate that inclusion of DTX molecules in the
CD cavities of the loaded NSs weakens such interactions and
stabilize the smaller species. Some pomegranate-like aggregates
with varied sizes (30–60 nm) and morphologies, resulting
from association of the elemental 15 nm nanoparticles, can
nevertheless be observed in the micrographs of the DTX-loaded
NSs (Figure 2C), which is probably the reason of the increased
polydispersity of loaded as compared with blank NSs determined
by DLS (Table 1). This behavior can be rationalized considering
TABLE 1 | Hydrodynamic diameter (nm), polydispersity index (PI) and
ζ-Potential (mV) of blank and DTX-loaded nanospheres (NS) and
nanocapsules (NC) prepared from 1 and 2.
Formulation Size (nm) PI ζ-Potential (mV)
1 blank NS 129 ± 1 0.04 ± 0.03 −31 ± 2
1 blank NC 120 ± 1 0.22 ± 0.01 −37.0 ± 1.6
2 blank NS 189 ± 1 0.05 ± 0.01 −34.2 ± 0.1
2 blank NC 152 ± 1 0.26 ± 0.02 −35.0 ± 0.9
1 DTX-NS 35 ± 1 0.28 ± 0.02 −13.3 ± 0.7
1 DTX-NC 267 ± 2 0.17 ± 0.02 −16.4 ± 0.9
2 DTX-NS 19.8 ± 0.3 0.23 ± 0.01 −12.7 ± 0.4
2 DTX-NC 209 ± 4 0.15 ± 0.01 −19.9 ± 0.8
Data show mean ± SD of three independent determinations.
that the docetaxel molecules at the external shell can bridge βCD
moieties at the surface of different NSs, since DTX possesses
two aromatic rings fitting well in the βCD cavity. The ability of
DTX to cluster molecular βCD derivatives has been previously
documented (Benito et al., 2004).
Docetaxel Release from CA4-βCD
Nanospheres and Nanocapsules
The docetaxel release kinetics followed a hyperbolic profile
both for the DTX-NS and DTX-NC formulations, with an
initial burst (6–8 h) followed by a sustained delivery over
30–60 h (Figure 3). The nanoparticles obtained from giant
surfactant 1, containing four hexyl chains at the calix[4]arene
MNP module, exhibited significantly longer DTX release times
as compared with formulations prepared from 2, which instead
have four dodecyl chains at the CA4 component. This result
is consistent with the strong dependence of the properties of
nanostructured materials assembled from giant molecules on
chemical modifications in the MNP components (Huang et al.,
2015).
Given the aforementioned very significant changes in the
surface properties of the NSs and the NCs upon loading with
DTX, it seems reasonable to speculate that the fast-releasing
DTX fraction corresponds to the drug hosted in the outer
βCD shell, whereas the slow-releasing portion accounts for
the drug encapsulated in the hydrophobic CA4-encircled core.
In the case of the NCs, the fast-releasing fraction represents
about 60% of the total drug, independently of the giant
amphiphile structure (1 or 2). However, the measured DTX-
loading capabilities indicate an average 2.5:1 molar DTX:giant
amphiphile ratio for 1-NS and 2-NS, meaning that the maximum
theoretical fraction of the drug hosted in βCD cavities (supposing
full occupation of the βCD cavities and a 1:1 DTX:βCD
stoichiometry) is 40%. The results can be rationalized assuming
that part of the fast-releasing DTX fraction is indeed hosted in the
intermediate region defined by the spacer linking the βCD and
CA4 modules, which remains relatively flexible and open. In the
case of the NCs, the fast releasing DTX fraction is much smaller
than in the case of the NSs, about 25% of the total drug. This
is in agreement with the proportionally much lower volume of
the βCD shell in the NC constructs, where the giant amphiphile
molecules are presumed to form a monolayer coating the oily
nanodrops.
Cytotoxic Action of DTX-Loaded
Nanoparticles
The cytotoxic effect of DTX-loaded NSs and NCs, prepared from
the βCD-CA4 amphiphilic heterodimers 1 and 2, was tested
on prostate and glioblastoma tumoral cell lines by exposing
them to increasing concentrations of the different nanoparticle
formulations for 72 h. Total DTX concentration encapsulated
in the nanoparticles ranged from 1 nM to 1 µM. As a positive
control, the same cells were exposed to free DTX (13% ethanol
solution) at the same concentrations. DTX is one of the drugs
used in the first-line treatment of PCa. In this work we tested the
effects of the giant surfactant-based DTX formulations on two
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FIGURE 2 | Representative cryo-TEM images of unloaded nanospheres (A) and nanocapsules (B) as well as docetaxel-loaded nanospheres (C) and
nanocapsules (D) prepared from heterodimer 1. In the absence of DTX, NS and NC of similar sizes (about 80 nm diameter) are observed (A,B). After DTX-loading,
NS size drastically decrease and entities of about 15 nm become observable, which eventually associate to give pomegranate-like aggregates (C). On the contrary,
NC size increases after DTX loading to about 150 nm diameter (D). Morphology changes after DTX loading are consistent with alteration of the surface properties of
the nanosystems, especially for NS, due to the presence of encapsulated DTX molecules in the peripheral βCD cavities.
human PCa cell lines: LnCaP, which is hormone-sensitive and
represents an early stage of PCa, and PC3, which is more resistant
to chemotherapy and is a model for hormone-refractory PCa.
As shown in Figure 4, DTX-loaded nanocapsules engineered
from macromolecular heterodimer 2 were significantly more
efficient than free DTX at inducing LnCaP tumoral cell death
at concentrations above 1 nM. The DTX-loaded nanospheres
obtained from heterodimers 1 and 2 were comparatively less
effective, but exhibited an efficacy similar to that of free DTX.
Regarding PC3 cells, DTX-loaded nanocapsules formulated with
heterodimer 1 showed a cytotoxic effect comparable to free DTX,
with the other formulations being less effective than free DTX
(Figure 5). It is important to note that the toxicity of free DTX
in PC3 cells is reduced in comparison to that observed for
LnCaP cells. This is consistent with the higher resistance to DTX
observed in hormone-independent advanced PCa.
Docetaxel has been also used to treat metastasized
glioblastoma (Astner et al., 2006). In this sense, the different
DTX-loaded nanoparticles prepared in this work induced
human glioblastoma U87 cell death in 72 h. DTX-loaded
nanospheres prepared from heterodimer 2, which exhibits the
fastest DTX release profile of all four assayed nanoformulations,
proved the most efficacious, inducing tumoral cell death levels
analogous to those obtained by the ethanolic free DTX at
100-nM concentration (Figure 6). In stark contrast, DTX-loaded
nanocapsules formulated from heterodimer 1, which shows the
slowest release kinetics, turned out to be the most efficient in rat
glioblastoma C6 cells, which offer a widely used murine model
for human glioblastoma (Figure 7). No toxicity was observed for
the blank nanoparticles in any of the four cell lines studied (data
not shown).
DISCUSSION
In this work we have formulated self-assembled nanoparticles
from giant surfactants composed of two covalently connected
MNP entities; namely, a hydrophilic β-cyclodextrin and a
hydrophobic calix[4]arene module. Our purpose was twofold:
(a) to probe the suitability of the heterodimeric CA4-βCD
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FIGURE 3 | Release profiles of docetaxel (DXT) as a function of time.
The figure represents DTX release profile from. (A) DTX-loaded heterodimer 1
nanocapsules (#); or nanospheres () and (B) DTX-loaded heterodimer 2
nanocapsules ( ) or nanospheres (). Experiments were performed in PBS
(pH 7.4) at 37◦C.
prototype as a versatile platform to optimize drug encapsulation,
delivery and release for a given cell type by finely tuning the
primary macromolecular structure and/or the architecture of
the nanoassembly; and (b) to develop new DTX formulations
with increased water solubility and bioavailability, without the
need for a co-solvent, thus retaining full anticancer efficacy.
As a proof of concept, we have engineered a short library
of four nanosystems, two having nanosphere-type topology
and two with a nanocapsule-type arrangement, from the CA4-
βCD heterodimers 1 and 2. All the NS and NC constructs
were characterized before and after loading with DTX and
their antitumoral action was evaluated in two prostatic cancer
and two glioblastoma cell lines and compared with a free
DTX formulation, containing 13% ethanol and Polysorbate 80,
currently used in hospitals (Taxotere R©).
The CA4-βCD giant surfactants 1 and 2 central to this
work were efficiently obtained by high-yielding “click”-type
thiourea coupling reactions between the isothiocyanate-
armed tetraalkylated CA4 derivative 3 or 4, which provides
the hydrophobic MNP component in the final amphipathic
macromolecular adduct, and the amine-equipped βCD
FIGURE 4 | Antitumoral effect of free and encapsulated docetaxel on
LnCaP human prostate cancer (PCa) cells. LnCaP cancer cells were
exposed to increasing concentrations of either free DTX (N) or docetaxel
encapsulated in heterodimer 1 nanocapsules (#); heterodimer 1 nanospheres
(); heterodimer 2 nanocapsules ( ) or heterodimer 2 nanospheres () for
72 h. LDH release to the medium was considered an index of cellular death.
Data represent mean ± SEM of 10 to 18 cells. ∗p < 0.05,∗∗p < 0.01,
∗∗∗p < 0.001 when compared to free DTX.
derivative 5, which supplies the hydrophilic MNP module
(Figure 1). We must bear in mind that the calix[4]arene scaffold,
in its cone conformation, offers an excellent platform for tight
compaction of hydrophobic tails located at its narrower rim,
which enhances the giant surfactant system self-assembling
capabilities in an aqueous environment (Gallego-Yerga et al.,
2015b). In the resulting nanoaggregates, the CA4 moieties will
be located in the core, providing a hydrophobic matrix that is
expected to be well-suited to accommodate hydrophobic drugs.
The drug loading capacity in the nanoparticle interior and the
release kinetics will depend on the architecture of the assembly
(NS or NC) and on the nature of the hydrophobic tails installed
at the phenolic oxygen atoms (hexyl for 1 and dodecyl for 2). The
β-cyclodextrin component will remain instead at the external
shell of the nanosystems, in contact with the bulk medium.
The βCD cavities will be then available for encapsulating either
additional drug or a third species, which can be exploited
to program different drug release profiles or to modify the
nanoparticle surface, e.g., by supramolecular incorporation
of functional elements for targeting purposes. It should be
emphasized that contrary to other giant amphiphiles based
in block copolymers (Wilks et al., 2013) thereby intrinsically
polydisperse, the CA4-βCD giant surfactants considered in this
work are single isomers with perfectly defined molecular
structure and obtained in genuine monodisperse form.
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FIGURE 5 | Antitumoral effect of free and encapsulated docetaxel on
PC3 human PCa cells. PC3 cancer cells were exposed to increasing
concentrations of either free DTX (N) or docetaxel encapsulated in
heterodimer 1 nanocapsules (#); heterodimer 1 nanospheres ();
heterodimer 2 nanocapsules ( )or heterodimer 2 nanospheres () for 72 h.
LDH release to the medium was considered an index of cellular death. Data
represent mean ± SEM of 16 to 44 cells. ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001 when compared to free DTX.
Differences in their self-assembling properties can be thus
directly related to structural differences at the atomic level.
The two giant surfactants 1 and 2 allowed accessing either
nanospheres or nanocapsules after nanoprecipitation by
dropping a methanol solution into a water phase, depending on
whether or not the organic solvent additionally incorporates a
non-ionic hydrophilic surfactant or pharmaceutically approved
synthetic triglycerides, respectively. DTX was efficiently
integrated into the NS and NC formulations by co-dissolving
with 1 or 2 prior to nanoprecipitation. Indeed, drug loading
capabilities higher that 75% were achieved in all cases, which
rank among the highest reported for DTX nanocarriers.
Drug loading had a significant impact on the nanoassembly
properties. Thus, the size of the nanospheres was very
significantly decreased after DTX incorporation, whereas that of
the nanocapsules experienced only a slight increase (Figure 2).
Probably, inclusion of a fraction of the drug in the cavities of
the βCD modules affects their capacity for hydrogen-bonding
interplay, preventing aggregation phenomena. Indeed, the cryo-
TEM micrographs of the DTX loaded nanospheres formulated
with 1 (Figure 2C) show the presence of small (15 nm) spherical
entities that probably engage in hierarchical self-assembling
in the absence of the drug, affording higher (about 100 nm)
nanoparticles (Figure 2A). This observation is in full accordance
with previous atom force microscopy data (Gallego-Yerga et al.,
2014).
FIGURE 6 | Antitumoral effect of free and encapsulated docetaxel on
U87 human glioblastoma cancer cells. U87 cancer cells were exposed to
increasing concentrations of either free DTX (N) or docetaxel encapsulated in
heterodimer 1 nanocapsules (#); heterodimer 1 nanospheres ();
heterodimer 2 nanocapsules ( ) or heterodimer 2 nanospheres () for 72 h.
LDH release to the medium was considered an index of cellular death. Data
represent mean ± SEM of 16 to 22 cells. ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001 when compared to free DTX.
Hydrodynamic diameters determined by DLS were overall
consistent with cryo-TEM data, considering the different
operational principles of both techniques (Geze et al., 2004).
DTX-loading also had a significant impact on the surface charge
of the nanoparticles. The ζ potential increased by about 20 mV
when formulated with the drug as compared with blank NSs or
NCs (from about −35 to −15 mV), strongly supporting that the
drug locates in part at the external shell, probably after partial
inclusion in the cavities of the βCD moieties. Indeed, it has
been previously shown that DTX can form inclusion complexes
with βCD derivatives in which an aromatic ring of the DTX
molecule is hosted inside the βCD cavity (Benito et al., 2004).
The stability of these complexes is enhanced if the two phenyl
moieties in DTX can interact simultaneously with two βCD units,
which is likely the case at the surface of the CA4-βCD assemblies.
The capacity of DTX to bridge βCD units can also explain the
presence of pomegranate-like aggregates in the DTX-loaded NSs
revealed by cryo-TEM (Figure 2C), which correlates with the
higher polydispersity index determined by DLS as compared to
blank NSs. The ability of the nanoaggregates to retain DTX at
the hydrophilic corona through inclusion phenomena is probably
further enhanced by the multivalent presentation of βCD motifs,
which likely favors sliding and rebinding processes of the drug.
Both the nanospheres and the nanocapsules thus behave as
multicavity systems with at least two functional regions: the core
and the shell. A fraction of the loaded DTX will be encapsulated
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FIGURE 7 | Antitumoral effect of free and encapsulated docetaxel on
rat glioblastoma C6 cancer cells. C6 cancer cells were exposed to
increasing concentrations of either free DTX (N) or docetaxel encapsulated in
heterodimer 1 nanocapsules (#); heterodimer 1 nanospheres ();
heterodimer 2 nanocapsules ( ) or heterodimer 2 nanospheres () for 72 h.
LDH release to the medium was considered an index of cellular death. Data
represent mean ± SEM of 20 to 32 cells. ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001when compared to free DTX.
in the inner core, relatively isolated from the environment, and
another fraction will stay at the shell and be partially exposed to
the medium.
The profiles of DTX release kinetics from DTX-NS and
DTX-NC formulations are overall compatible with the core-
shell architecture of the assemblies and the proposed differential
distribution of the stored drug between these two distinct
compartmented regions. Thus, the curves reveal an initial fast
release period that likely accounts for the exchange of the DTX
molecules included in βCD cavities or entrapped in the region
defined by the segment connecting the βCD and CA4 modules. If
this assumption is correct, the DTX fraction hosted in the shell
would account for about 60% in the case of the nanospheres and
25% in the case of the nanocapsules.
Diffusion of the drug out of the nanoassembly core is a
slower process and is probably responsible for the sustained
release period. The presence of the lipidic phase in the core of
nanocapsules leads to a delayed DTX release as compared with
the corresponding nanosphere formulations. Most notably, DTX
release was found to be significantly faster from DTX-loaded
nanospheres and nanocapsules assembled from giant surfactant 2
as compared with the analogous formulations prepared from the
homologous CA4-βCD heterodimer 1, even though no relevant
differences were observed in the nanoparticle sizes, topologies
or ζ-potential. It is possible that the higher conformational
flexibility of dodecyl over hexyl tails translates into less compact
arrangements after self-assembly, facilitating the exchange
between the nanoparticle core and the bulk aqueous exterior. The
interplay of molecular (hexyl or decyl chains at the CA4 moiety)
and nanostructure features (NS or NC arrangement) results in a
gradation of the DTX release rate that follows the order 2 DTX-
NS>1 DTX-NS≈2 DTX-NC>1 DTX-NC. This result highlights
the unique possibilities for finely programming the properties
of nanometric devices assembled from giant surfactants through
the controlled chemical modification of a single individual MNP
component. Interestingly, all NSs and NCs prepared in this
work, either blank or DTX-loaded, remained stable as colloidal
solutions at pH 7 for over 30 days at 25 or 37◦C, as inferred
from the absence of any precipitate and the virtually identical
DLS and cryo-TEM results recorded over this time period. The
DTX release kinetics from the drug-loaded nanosystems were
also virtually identical after storage, meaning that the relatively
fast release observed for NSs must be ascribed to the particular
characteristics of this self-assembled arrangement and not to
stability problems.
The main drawback of current commercial DTX formulations
is their low water solubility. This requires dilution with ethanol
before administration of the drug, which exacerbates the already
high intrinsic DTX toxicity (Zhang and Zhang, 2013). The giant
amphiphile-based nanosphere and nanocapsule formulations
studied here are all able to efficiently incorporate DTX, solubilize
it in water without the need for a co-solvent and fully release
the drug payload in a biological environment over a 30 to
60 h period, yielding effective DTX concentrations that are
able to induce tumoral cancer cell death. The vials obtained
after the formulation procedure described in Methods contained
950 mg of DTX and about the same amount of excipients
(including the giant amphiphile 1 or 2, surfactants and, in the
case of NCs, the oil component) in 1 mL of plain water, that
is a mass ratio of drug to excipient very close to unity. For
comparison, the commercial formulation of DTX (Taxotere R©)
contains 40 mg of DTX and 1040 mg of Polysorbate 80 in
1 mL of 13% aqueous ethanol, meaning a mass ratio of drug to
excipient of 1:26. Another important advantage of the new NS
and NC formulations is that they remained stable for periods
over 30 days at room temperature, whereas Taxotere must be
formulated from a solution of anhydrous DTX in Polysorbate
80 and used in 8 h due to drug instability in the hydroethanolic
medium.
Most of the cell lines tested for sensitivity to DTX-induced
cell death had IC50 values between 5 and 50 nM (Clarke and
Rivory, 1999). This was also the case for the four cell lines
considered in this study (LnCaP, PC3, U87 and C6) when treated
with the ethanol-diluted DTX formulation, as well as with the
different DTX-loaded nanoparticles. We therefore focused on
the range of 10 to 100 nM total DTX concentration to compare
the effectiveness of free versus encapsulated DTX formulations
and to analyze the potential advantages of encapsulating the
drug in the giant surfactant-based nanocarriers. In all cases,
the corresponding blank nanospheres or nanocapsules prepared
from 1 or 2 at identical concentration, used as controls
in parallel assays, did not promote any cytotoxicity. The
anticancer effectiveness of the formulations was found to be
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highly dependent on the cell linage, emphasizing the need
for approaches that permit optimization of the carrier on
a case-by-case basis. Giant surfactants are particularly well-
suited for that purpose. Thus, DTX-loaded nanocapsules were
more effective than the corresponding nanospheres in human
LnCap cells, which points to bigger nanoparticles favoring
the anticancer activity in this particular cell type. For a
given nanocarrier configuration (NS or NC), the efficiency at
promoting LnCap cell death increased with the drug release
rate, with the optimal DTX-NC formulation prepared from
heterodimer 2 exhibiting a much higher efficiency than the
commercial free DTX formulation in the 10 to 100 nM range. In
stark contrast, the hormone-resistant human PCa PC3 cell line
was more sensitive to small size DTX-loaded nanospheres than
to the corresponding nanocapsules. The DTX-NS formulation
assembled from heterodimer 1, which has a significantly slower
release profile than the analogous DTX-NS formulation prepared
from 2, yielded the best results of the four systems tested,
showing a similar cytotoxic effect to the free DTX formulation.
In the case of the human glioma U87 cell line, the DTX-loaded
nanospheres engineered from the CA4-βCD heterodimer 2,
which combine small size and fast drug release, were significantly
more efficacious than the other three nanoformulations assayed,
whereas the rat glioblastoma cell line C6 was instead more
sensitive to the higher size and slow DTX releasing nanocapsules
assembled from 1. In both cases the optimal system behaved as
efficiently as the free DTX formulation in the same experimental
setting.
The differences observed in the sensitivity of the different cell
lines to the DTX-loaded nanoparticles might reflect differences
in the ability of the nanosystems to cross the plasma membrane
of each cell type and dissimilarities in their susceptibility to
either a slow or fast drug release profile. Treating human
PCa LnCaP cell line with DTX-loaded nanocapsules prepared
from heterodimer 2 represents a particularly favorable scenario,
with the giant surfactant-based nanoformulation being markedly
superior at inducing cell death as compared with the free
DTX ethanolic formulation. Most importantly, by properly
choosing the giant surfactant precursor (1 or 2) and the optimal
nanoassembly configuration (NS or NC), it was possible to find
a nanoformulation for every cell type that performed at least
as efficiently as free DTX, ensuring full water solubility without
the need for any co-solvent. The core-shell architecture of the
nanocarriers, which exposes the βCD component of the CA4-
βCD heterodimeric building blocks to the bulk, further opens
the door to the possibility of supramolecular decoration of the
NS or NC surface with targeting groups for site specific DTX
delivery to tumoral tissues (Yin et al., 2013). Encapsulation of
the drug is additionally expected to improve its bioavailability
and decrease the variability of the treatment by avoiding
premature clearance through biological fluids. The docetaxel-
mediated clinical effect and its hematologic toxicity have been
found to correlate very well with the free drug concentration
that is not bound to serum proteins (Baker et al., 2005),
which amounts to only 5% of the total drug concentration in
plasma. The remaining 95% of the drug is bound mainly to
albumin and α1-acid glycoprotein (AAG). The large disparity
in AAG levels among different patients is largely responsible
for the observed discrepancies in DTX effectiveness and toxicity
(Bruno et al., 1998). Carbohydrate coating is an efficient strategy
to prevent serum protein binding to nanoparticles, similarly
to polyethylene glycol “stealth” coating (Amoozgar and Yeo,
2012). The presence of glucose units at the outer surface of
the nanosystems assembled from CA4-βCD heterodimers was
indeed purposely intended to make the new DTX formulations
stealth.
To the best of our knowledge, the body of results
reported herein provides the first evidence of the potential
of the “macromolecular precise synthesis” and “giant
surfactant” concepts in strategies directed at optimizing
drug nanoformulations. By covalently connecting β-cyclodextrin
and calix[4]arene MNPs, heterodimers with perfectly controlled
structures can be accessed. The self-assembly of the resulting
CA4-βCD giant surfactants yields core-shell nanospheres or
nanocapsules, depending on the nanoprecipitation protocol,
with drug encapsulation and release properties that are closely
related to the primary macromolecular architecture. The
versatility of the prototype offers unprecedented opportunities to
conduct drug and cell-oriented SAR studies, as exemplified by the
set of data obtained on the anticancer activity of docetaxel-loaded
nanoassemblies against pancreatic and glioblastoma cells. Giant
amphiphile-based formulations surpassing or matching the
antitumoral activity of the free DTX formulation were identified
in all cases, overcoming the DTX water solubility problems. The
proposed self-assembled nanocarriers are further intended to
be biocompatible, to have a low propensity to undergo protein
serum adsorption and to be compatible with the incorporation
of targeting moieties for tumor-specific drug delivery, by virtue
of exposing cyclooligosaccharidic βCD units at their surface
(Mogosanu et al., 2016). This should allow them to bypass
healthy cells, thus reducing the side-effects associated with DTX
treatment. We are continuing to work along these lines in our
laboratories.
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